No Data
Cachet Pharmaceutical's (SZSE:002462) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Jiashitang: First Quarter Report 2025
Jiashitang: 2024 Annual Report Summary
Kashitang: 2024 Annual Report
Cachet Pharmaceutical (002462.SZ): Xu Xi was elected as Director.
On December 30, Geloonghui reported that Cachet Pharmaceutical (002462.SZ) announced that on December 30, 2024, the company held its third extraordinary Shareholder meeting of 2024, where the proposal on the election of a non-independent director was reviewed and approved, with Mr. Xu Xi officially becoming a non-independent director of the company's seventh Board of Directors. On the same day, the company held the fourteenth extraordinary meeting of the seventh Board of Directors, where the proposal on the election of the company's chairman was reviewed and approved, electing Mr. Xu Xi as the chairman of the company. According to the provisions of the Articles of Association, Mr. Xu Xi also serves as the legal representative of the company, with a term starting from the date of the Board review until the end of this Board.
Cachet Pharmaceutical's (SZSE:002462) Shareholders Have More To Worry About Than Only Soft Earnings
Benign Growth For Cachet Pharmaceutical Co., Ltd. (SZSE:002462) Underpins Stock's 30% Plummet
